Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area

Imagem de Miniatura
Arquivos
art_SHIMABUCO_Ankylosing_spondylitis_and_psoriatic_arthritis_revisiting_screening_of_2020.PDF.pdf (209.59 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2020
DOI
SciELO
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
Citação
CLINICS, v.75, article ID e1870, 7p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: To retrospectively evaluate the performance and distinctive pattern of latent tuberculosis (TB) infection (LTBI) screening and treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) under anti-tumor necrosis factor (TNF) therapy and determine the relevance of re-exposure and other risk factors for TB development. METHODS: A total of 135 and 83 patients with AS and PsA, respectively, were evaluated for LTBI treatment before receiving anti-TNF drugs via the tuberculin skin test (TST), chest radiography, and TB exposure history assessment. All subjects were evaluated for TB infection at 3-month intervals. RESULTS: The patients with AS were more often treated for LTBI than were those with PsA (42% versus 30%, p=0.043). The former also presented a higher frequency of TST positivity (93% versus 64%, p=0.002), although they had a lower frequency of exposure history (18% versus 52%, p=0.027) and previous TB (0.7% versus 6%, p=0.03). During follow-up [median, 5.8 years; interquartile range (1QR), 2.2-9.0 years], 11/218 (5%) patients developed active TB (AS, n=7; PsA, n=4). TB re-exposure was the main cause in seven patients (64%) after 12 months of therapy (median, 21.9 months; IQR, 14.2-42.8 months) and five LTBI-negative patients. TB was identified within the first year in four patients (36.3%) (median, 5.3 months; IQR, 1.2-8.8 months), two of whom were LTBI-positive. There was no difference in the TB-free survival according to the anti-TNF drug type/class; neither synthetic drug nor prednisone use was related to TB occurrence (p > 0.05). CONCLUSION: Known re-exposure is the most critical factor for incident TB cases in spondyloarthritis. There are also some distinct features in AS and PsA LTBI screening, considering the higher frequency of LTBI and TST positivities in patients with AS. Annual risk reassessment taking into consideration these peculiar features and including the TST should be recommended for patients in endemic countries.
Palavras-chave
Latent Tuberculosis, Spondyloarthritis, Tuberculin Skin Test, Mycobacterium tuberculosis, Tumor necrosis factor-alpha
URI
https://observatorio.fm.usp.br/handle/OPI/38265
Referências
  1. Bombardier C, 2012, J RHEUMATOL, V39, P1583, DOI 10.3899/jrheum.120165
  2. Bonfiglioli KR, 2014, INT J TUBERC LUNG D, V18, P905, DOI 10.5588/ijtld.13.0755
  3. Cantini F, 2015, AUTOIMMUN REV, V14, P503, DOI 10.1016/j.autrev.2015.01.011
  4. Cantini F, 2014, J RHEUMATOL, V41, P47, DOI 10.3899/jrheum.140102
  5. Cecconi M, 2018, J CLIN RHEUMATOL
  6. Chen DY, 2008, ARTHRIT RHEUM-ARTHR, V59, P800, DOI 10.1002/art.23705
  7. Dixon WG, 2010, ANN RHEUM DIS, V69, P522, DOI 10.1136/ard.2009.118935
  8. Gomes CMF, 2015, MEM I OSWALDO CRUZ, V110, P921, DOI 10.1590/0074-02760150235
  9. Furst DE, 2013, ANN RHEUM DIS, V72, P2, DOI 10.1136/annrheumdis-2013-203348
  10. Garziera G, 2017, CLIN RHEUMATOL, V36, P1891, DOI 10.1007/s10067-017-3714-6
  11. Gomez-Reino JJ, 2007, ARTHRIT RHEUM-ARTHR, V57, P756, DOI 10.1002/art.22768
  12. Greenberg JD, 2010, ANN RHEUM DIS, V69, P380, DOI 10.1136/ard.2008.089276
  13. da Mota LMH, 2015, REV BRAS REUMATOL, V55, P390, DOI [10.1016/j.rbr.2015.01.006, 10.1016/j.rbre.2015.01.006]
  14. da Mota LMH, 2015, REV BRAS REUMATOL, V55, P281, DOI [10.1016/j.rbr.2014.06.006, 10.1016/j.rbre.2014.06.006]
  15. Hsia EC, 2013, ARTHRIT CARE RES, V65, P309, DOI 10.1002/acr.21788
  16. Hsia EC, 2012, ARTHRITIS RHEUM-US, V64, P2068, DOI 10.1002/art.34382
  17. Iannone F, 2014, J RHEUMATOL, V41, P41, DOI 10.3899/jrheum.140101
  18. Jung SM, 2015, INT J RHEUM DIS, V18, P323, DOI 10.1111/1756-185X.12530
  19. Kim EM, 2011, J RHEUMATOL, V38, P2218, DOI 10.3899/jrheum.110373
  20. KIM JI, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1016/J.SEMAR
  21. Kisacik B, 2016, J RHEUMATOL, V43, P524, DOI 10.3899/jrheum.150177
  22. Laurindo IM, 2004, EULAR 2004
  23. Leung CC, 2011, EUR RESPIR J, V37, P690, DOI 10.1183/09031936.00079310
  24. Lorenzetti R, 2014, ANN MED, V46, P547, DOI 10.3109/07853890.2014.941919
  25. Malaviya AN, 2018, INT J RHEUM DIS, V21, P1563, DOI 10.1111/1756-185X.13261
  26. Mariette X, 2012, ANN RHEUM DIS, V71, P1783, DOI 10.1136/annrheumdis-2011-200408
  27. Mikulska M, 2018, CLIN MICROBIOL INFEC, V24, pS71, DOI 10.1016/j.cmi.2018.02.003
  28. Ministerio da Saude, 2018, PROT LAT TUB INF SUR
  29. Ministerio da Saude, 2011, GUID CONTR TUB BRAZ
  30. Ministerio da Saude, BRAS LIVR TUB EV CEN
  31. Minozzi S, 2016, EXPERT OPIN DRUG SAF, V15, P11, DOI 10.1080/14740338.2016.1240783
  32. Munoz L, 2015, CLIN INFECT DIS, V60, P349, DOI 10.1093/cid/ciu796
  33. Park JH, 2009, J RHEUMATOL, V36, P2158, DOI 10.3899/jrheum.090150
  34. Ribeiro ACM, 2019, BIOBA DABRASIL ANN R, V78, P1129
  35. Sandgren A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1550-y
  36. Sartori NS, 2020, CLIN RHEUMATOL, V39, P1439, DOI 10.1007/s10067-019-04866-x
  37. Shobha V, 2019, INT J RHEUM DIS, V22, P280, DOI 10.1111/1756-185X.13376
  38. Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641
  39. Soare A, 2018, CLIN RHEUMATOL, V37, P2391, DOI 10.1007/s10067-017-3916-y
  40. Solovic I, 2010, EUR RESPIR J, V36, P1185, DOI 10.1183/09031936.00028510
  41. Walls RS, 2008, LANCET INFECT DIS, V8, P601, DOI 10.1016/S1473-3099(08)70227-5
  42. Wang X, 2019, RHEUMATOLOGY, V58, P803, DOI 10.1093/rheumatology/key364
  43. Yonekura CL, 2017, REV BRAS REUMATOL, V57, P477, DOI 10.1016/j.rbr.2017.05.003

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - ODS/03